Diagnosis and biomarkers of predementia in Alzheimer's disease
2010

Diagnosis and biomarkers of predementia in Alzheimer's disease

publication Evidence: high

Author Information

Author(s): Forlenza Orestes V, Diniz Breno S, Gattaz Wagner F

Primary Institution: Laboratory of Neuroscience (LIM 27), Department and Institute of Psychiatry, Faculty of Medicine, University of São Paulo, São Paulo, Brazil

Hypothesis

The early diagnosis of Alzheimer's disease relies on the hypothesis that pharmacological interventions with disease-modifying compounds are likely to produce clinically relevant benefits if started early enough in the continuum towards dementia.

Conclusion

The study emphasizes the importance of developing biomarkers for early diagnosis of Alzheimer's disease to improve clinical outcomes.

Supporting Evidence

  • Alzheimer's disease is the most common dementing disorder in older people.
  • More than 80 million individuals are expected to be affected by Alzheimer's disease by 2040.
  • Biomarkers can help identify individuals at risk of developing dementia.

Takeaway

This study talks about how doctors can find out if someone might get Alzheimer's disease before they show serious symptoms, using special tests and scans.

Methodology

The review discusses clinical characteristics and recent developments in biomarker research for early diagnosis of Alzheimer's disease.

Limitations

The translation of current knowledge into clinical practice still requires methodological pruning and guidance by operational criteria.

Digital Object Identifier (DOI)

10.1186/1741-7015-8-89

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication